AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation

News
1

The data presented here strongly indicate that due to its high oral bioavailability, extremely high selectivity, and potency to block the 5-HT6 receptor, AVN-492 is a very promising tool for evaluating the role the 5-HT6 receptor might play in cognitive and neurodegenerative impairments.

AVN-492 is an excellent drug candidate to be tested for treatment of such diseases, and is currently being tested in Phase I trials.

7 Likes
2

Its mainly for cognitive symptoms. …

2 Likes
3

Tackling cognitive symptoms is important.

4 Likes
4

Wow, is this kind of like avn-211? I know a lot of atypicals antagonise 5ht6 improving cognition.

1 Like
5

I hope this don’t last too much :pray:

2 Likes